Tumor Immunity Overview

Principles

Definition

Tumor immunity is a research field that investigates the intricate and dynamic interactions between the host's immune system and malignant cells. This field encompasses the mechanisms of immune recognition of tumor antigens, the nature of anti-tumor immune responses, and the strategies employed by tumors to evade immune surveillance, providing crucial insights for the development and application of cancer immunotherapies.

Ontological type

Immunotherapy Strategies

Key Mechanisms

Tumor Immune Evasion

Key developments

Key Figures

Antigen and Dendritic Foundations era

Steven A. Rosenberg [1] is associated with Harvard University [3] and Johns Hopkins University [4] during the Antigen and Dendritic Foundations era. His key contributions include the demonstration of interleukin-2–activated killer cell activity against fresh solid tumors using autologous lymphocytes [6], the cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating tumors [7], and the identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection [8], all of which articulated antigen-driven mechanisms as central to tumor immunity. James P. Allison [2] is associated with Harvard University [3] and the University of California, San Francisco [5] in this era. His work on CTLA-4 blockade enhancing antitumor immunity [9] and on combination immunotherapies using anti–CTLA-4 with GM-CSF–producing vaccines inducing rejection of melanoma and related depigmentation [10] helped define how checkpoint modulation and vaccine context shape tumor immune responses in this period.

Checkpoint and Combination Immunotherapy era

Wolf H. Fridman [1], a leading figure in tumor immunology, conducted influential work across Innsbruck Medical University [3] and Université Paris Cité [4] during the checkpoint and combination immunotherapy era. His analyses revealed that Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome [7], and that Effector Memory T Cells correlate with early metastasis and survival [8], establishing the prognostic and mechanistic relevance of tumor immune contexture for guiding therapies [9]. Caroline Robert [2] is associated with Harvard University [5] and the Massachusetts Institute of Technology [6] in this era. Her pivotal contribution PD-1 blockade induces responses by inhibiting adaptive immune resistance [10], illustrating checkpoint blockade as a therapeutic lever that enabled combinations in this era.

Neoantigen-Driven Precision Immunity era

Janis M. Taube [1] is associated with Johns Hopkins University [3] and University of Washington [4] during the Neoantigen-Driven Precision Immunity era. Her key contributions in this era include linking mismatch repair deficiency to enhanced PD-1 blockade responsiveness, as demonstrated by the paper Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade [6], which underscored the importance of genomic instability as a predictive biomarker. Drew M. Pardoll [2] is affiliated with Harvard University [5] and Johns Hopkins University [3] in this era. His work likewise drew on the same study, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade [6], a contribution that helped advance neoantigen-driven biomarker integration in immunotherapy.